CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 254 filers reported holding CRISPR THERAPEUTICS AG in Q4 2019. The put-call ratio across all filers is 1.45 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $379,000 | +52.8% | 5,811 | +46.5% | 0.00% | +100.0% |
| Q1 2022 | $248,000 | -8.8% | 3,966 | +62.5% | 0.00% | 0.0% |
| Q3 2021 | $272,000 | -31.0% | 2,441 | 0.0% | 0.00% | -50.0% |
| Q2 2021 | $394,000 | +31.8% | 2,441 | -0.9% | 0.00% | 0.0% |
| Q1 2021 | $299,000 | -20.3% | 2,463 | +0.3% | 0.00% | 0.0% |
| Q4 2020 | $375,000 | +197.6% | 2,456 | +61.6% | 0.00% | +100.0% |
| Q3 2020 | $126,000 | -48.1% | 1,520 | -54.2% | 0.00% | 0.0% |
| Q2 2020 | $243,000 | +57.8% | 3,320 | +30.2% | 0.00% | 0.0% |
| Q1 2020 | $154,000 | 0.0% | 2,550 | 0.0% | 0.00% | 0.0% |
| Q4 2019 | $154,000 | +30.5% | 2,550 | -12.1% | 0.00% | 0.0% |
| Q3 2019 | $118,000 | -58.2% | 2,900 | -51.7% | 0.00% | 0.0% |
| Q2 2019 | $282,000 | +340.6% | 6,010 | +233.9% | 0.00% | – |
| Q1 2019 | $64,000 | +25.5% | 1,800 | 0.0% | 0.00% | – |
| Q4 2018 | $51,000 | -63.0% | 1,800 | -23.4% | 0.00% | -100.0% |
| Q2 2018 | $138,000 | – | 2,349 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Gilfoyle Management LLC | 150 | $6,376 | 12.96% |
| Versant Venture Management, LLC | 498,558 | $22,629,548 | 12.03% |
| NEA Management Company, LLC | 1,587,854 | $72,072,693 | 5.57% |
| ARK Investment Management | 7,163,118 | $325,133,913 | 2.49% |
| Nikko Asset Management Americas, Inc. | 3,465,470 | $157,263,029 | 1.88% |
| Integral Health Asset Management, LLC | 275,000 | $12,482,250 | 1.73% |
| Merlin Capital, Inc | 9,092 | $412,686 | 1.54% |
| Del-Sette Capital Management, LLC | 33,977 | $1,542,216 | 1.52% |
| Green Alpha Advisors, LLC | 34,880 | $1,583,203 | 1.22% |
| Ikarian Capital, LLC | 2,039 | $9,255,021 | 1.11% |